[The neurotropic activity of peptide immunomodulators].
Grechko. A T AT
Key Findings
- Thymogen displayed neuromodulating effects in a 4‑day open‑field test on animals
- It altered circadian rhythm and motor activity dynamics
- Its potency was lower than ethymizol, cerebrolysin, thymalin, and nootropil
Practical Outcomes
- The data suggest thymogen might have mild brain‑modulating properties, but the evidence is limited to animal behavior and is not strong enough to define a clear dosing or usage protocol for humans. Biohackers should view it as a low‑priority candidate pending human studies.
Summary
In a short animal study, the peptide thymogen showed some brain‑affecting activity, changing the animals' daily activity patterns and how they explore, but its effect was weaker than several other similar peptides and standard drugs.
Abstract
Four-day monitoring using standard methods of studying free group behavior of animals in an "open field" (Opto-Varimex, USA) showed that all the peptide immunomodulators under study possessed a neuromodulating effect comparable with that of known drugs. They change the character of the circadian rhythms of the animals' motor activity and the dynamics of extinction of the orientation-investigation reaction. In comparison with the control the activity of the drugs under study was distributed as follows: ethymizol > cerebrolysin > thymalin > nootropil > thymogen > T-activin > cortexin > dibazol.
Study Information
pubmed
1998